Seeking Alpha

Shares of BioCryst Pharmaceuticals (BCRX +3.4%) get a lift after the company reveals its BCX4208...

Shares of BioCryst Pharmaceuticals (BCRX +3.4%) get a lift after the company reveals its BCX4208 gout drug met its primary endpoint in a Phase 2b randomized, double-blind, dose-response study. CEO Jon Stonehouse says the next big step is to find a partner for lead development for the drug that he says has a market potential of $500M.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector